Indeed, the identification of this causal pathogenic mechanism has suggested a potential therapy for CCM disease based on inhibitors of RhoA activation and signaling, including statins and fasudil (Li and Whitehead, 2010, McDonald et al., 2012). This evidence concerns the gene RHOA and cerebral cavernous malformation.